September 5, 2013  |  Announcements

Cytobank is thrilled to be part of the Stanford-StartX Fund

The Stanford-StartX Fund is a joint venture between Stanford University, Stanford Hospital & Clinics (SHC) and StartX, a startup accelerator for Stanford-affiliated entrepreneurs, to fund the next generation of companies set to change the world.

We’re thrilled to announce that Cytobank has been chosen as one of two StartX companies to receive investment from the Stanford-StartX Fund.

We first built Cytobank to enable our own research projects as Stanford graduate students. We were among the first to show the importance of measuring information at the single cell level for diagnosis and treatments in leukemias and lymphomas, as well as the importance of incorporating cell type into drug discovery assays.

The need for a platform that unlocks the clinical potential in these single cell measurements  is what led us to found Cytobank Inc., (more at the Cytobank Story).

Single cell analysis has since then been recognized as the most important technology of the future of personalized medicine. The Cytobank platform is the engine behind landmark research in cell signaling and mass cytometry.  Cytobank is in use by thousands of researchers at top pharmaceutical and biotechnology companies as well as, the premier medical research institutions around the world.

Still, it just feels like we are getting started. The data keep getting bigger and the need for appropriate computation resources and analytics is more crucial than ever.

Today’s investment from the Stanford-StartX Fund will enable us to scale our infrastructure and move us closer to our ultimate goal of presenting this data in a useful, digestible and relevant manner to enable clinical decisions, and create life-saving medical breakthroughs.

We have a long way to go but it is an amazing feeling to have garnered such support from the Stanford and StartX community.

  – Nikesh

April 23, 2010  |  Announcements

Welcome to the Cytobank Blog

Here’s a quick post welcoming everyone to our brand new blog.  One of the things you can expect to see here are posts about our software releases, which will provide a list of new features and bug fixes that have just been launched to our production servers.  We’re also going to try to have discussions about various aspects of cytometry and ideally even some guest posts from our friends in industry and academia.

Please feel free to leave comments, feedback, and questions on our posts.  We’ll try to respond in a timely manner.

– Chris